F. Dimitriou

Has grant

Attending Physician, Head of Skin Cancer Center

University Hospital of Bern
Country flagSwitzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

The role of the microbiome and treatment response in rare melanoma subtypes

Open Date: 2024-06-01

Close Date: 2026-05-30

Grant: Close

Delineating the role of the microbiome and immunotherapy response across melanoma subtypes

Open Date: 2023-01-01

Close Date: 2025-01-01

Grant: Close

Multi-omic characterization of immune-related adverse events during treatment with immune checkpoint inhibitors in advanced melanoma: one step towards a personalized treatment

Open Date: 2023-01-01

Close Date: 2024-01-01

Grant: Close

Project support for the establishment of a national network for the documentation of side effects in skin cancer treatment («D-TOX» project)

Open Date: 2023-01-01

Close Date: 2024-01-01

Grant: Close

Investigating Immunotherapy-related toxicities in Melanoma: Characterization of serum cytokines during immune-related adverse events on anti-PD1 based immunotherapy for metastatic melanoma

Open Date: 2020-01-01

Close Date: 2022-01-01

Articles (8)

Year:

2025

Artificial intelligence (AI) systems substantially improve dermatologists’ diagnostic accuracy for melanoma, with explainable AI (XAI) systems further enhancing their confidence and trust in AI-driven decisions. Despite these advancements, there remains a critical need for objective evaluation of how dermatologists engage with both AI and XAI tools. In this study, 76 dermatologists participate in a reader study, diagnosing 16 dermoscopic images of melanomas and nevi using an XAI system that provides detailed, domain-specific explanations, while eye-tracking technology assesses their interactions. Diagnostic performance is compared with that of a standard AI system lacking explanatory features. Here we show that XAI significantly improves dermatologists’ diagnostic balanced accuracy by 2.8 percentage points compared to standard AI. Moreover, diagnostic disagreements with AI/XAI systems and complex lesions are associated with elevated cognitive load, as evidenced by increased ocular fixations. These insights have significant implications for the design of AI/XAI tools for visual tasks in dermatology and the broader development of XAI in medical diagnostics.

Year:

2025

Immune checkpoint inhibitor therapy (ICI)-induced myositis (irMyositis) occurs in about 1% of patients treated with anti-PD1 or anti-CTLA-4 antibodies and can be debilitating or even fatal. We compared gene expression profiles from skeletal muscle biopsies between irMyositis patients, patients with spontaneous dermatomyositis (DM, comprising anti-Mi2-positive and anti-TIF1-γ-positive subtypes), and non-diseased controls (NDC). We used the NanoString nCounter PanCancer Immune Profiling Panel to perform differential gene expression (DGE) and pathway enrichment analyses. We identified 93 differentially expressed genes (DEGs) across conditions. Gene set enrichment analysis (GSEA) suggested activation of interferon gamma (type-II IFN) and interferon alpha/beta (type-I IFN) signaling in irMyositis and DM, respectively. For instance, type-II IFN was upregulated exclusively in irMyositis when compared to DM, which conversely showed upregulation of effector genes downstream type-I IFN. The observed fold-change of a subset of 33 genes drove the GSEA. We further characterized the DEGs using network interaction and expression correlation analyses. This allowed us to describe potential differences between regulatory hubs and cells involved in irMyositis susceptible to ICI effects. For example, the downregulation of FOXP3 we observed together with the upregulation of the chemokine CCL14 in irMyositis may have been a consequence of T cell activation upon ICI therapy. The gene expression correlation and putative molecular interactions set irMyositis apart from DM, particularly with respect to IFN response and DGE of interactors of ICI protein targets (CTLA4, PD-1, PD-L1). Our results suggest new avenues for understanding immunotherapy-related adverse events.

Year:

2025

Year:

2025

Our primary objective was to estimate the overall response rate to immune checkpoint inhibitors (ICIs) in patients with locally advanced, multiply recurrent, or metastatic conjunctival melanoma treated with ICIs. A retrospective review of all consecutive conjunctival melanoma patients who were treated with ICI between October 2017 and January 2024 was carried out. The study included 16 patients with a median age of 66 years. The indications for ICI were locally extensive conjunctival melanoma in the eye/orbital area without nodal or distant metastasis in 10 patients, local recurrence of conjunctival melanoma and simultaneous nodal or distant metastasis in four patients, and metastatic conjunctival melanoma without local recurrence in two patients. Five patients received PD-1 inhibitor monotherapy with nivolumab or pembrolizumab; the other 11 received ipilimumab (CTLA-4 inhibitor) and nivolumab for several cycles and were then continued on nivolumab monotherapy ( n = 6) or not given additional ICI therapy ( n = 3). The number of cycles of ICI ranged from 2 to 25 (median, 13). Eight patients achieved a complete response. Six patients had progressive disease. The overall rate of objective response to ICI therapy was 63% (10 of 16), and for the subset of patients with local disease only, the objective response rate was 70% (7 of 10). In 14 patients (88%), orbital exenteration or additional extensive surgery was avoided; two patients had progression despite ICI and eventually needed an orbital exenteration. Future studies should aim to correlate biomarker data with response to ICI therapy in patients with conjunctival melanoma.

Year:

2025

Background Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, with programmed cell death protein 1 (PD-1) inhibitors—alone or in combination with cytotoxic T-lymphocyte–associated protein 4 or lymphocyte-activation gene 3 inhibitors—demonstrating significant efficacy. However, there is a critical lack of robust data to determine the optimal sequencing of these therapies for individual patients. In particular, the role of relatlimab+nivolumab (rela/nivo) within treatment sequences remains poorly defined. Choosing the right sequence is strategic, as an inappropriate order may compromise the effectiveness of subsequent treatments and limit long-term benefits. Methods This multicenter retrospective and prospective study evaluated 190 patients across three treatment arms: rela/nivo followed by ipilimumab+nivolumab (ipi/nivo) (arm A, N=40), ipi/nivo followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment sequencing on outcomes including response rate, progression-free survival, and overall survival (OS). Results The overall response rate to second treatment was highest in arm C (30.4%), followed by arm B (28.1%) and arm A (17.5%). Patients with secondary resistance to first-treatment ICIs had better responses to second-treatment ICIs than those with primary resistance, particularly in arm B (p=0026). Median OS from date of first ICI treatment was significantly longer in arms B (40.9 months) and C (42.5 months) compared with arm A (16.3 months). Conclusions Our findings indicate that rela/nivo may remain active following anti-PD-1 or ipi/nivo therapy. Additionally, our results suggest that sequencing ipi/nivo before rela/nivo may yield better outcomes than starting with rela/nivo. Patients who respond to the first combination regimen appear to derive greater benefit from the second. Further efforts are needed to optimize sequencing strategies in advanced melanoma, and future studies should consider the impact of prior treatment outcomes.

Year:

2025

Year:

2024

Background Immune checkpoint inhibitors (ICIs) have significantly improved survival in advanced melanoma but are associated with immune‐related adverse events (irAEs). This single center, cross‐sectional survey aimed to describe the long‐term symptom burden and impact on health‐related quality of life (HRQL) of advanced melanoma patients with sustained disease control following treatment with ICIs. Methods Advanced melanoma patients (stage IIB, III or IV, AJCCv8), treated with anti‐PD1‐based ICIs, who were off‐treatment and had at least 6 months follow‐up from their last infusion with an ongoing response in the metastatic setting or no evidence of disease recurrence in the adjuvant setting. A paper‐based questionnaire, consisting of the EORTC QLQ‐C30, EORTC QLQ‐FA12, and the PRO‐CTCAE was administered. Results Of 90 participants, 61 (68%) completed the questionnaire; 40 received single‐agent anti‐PD1, and 21 anti‐PD1/anti‐CTLA4. Thirty‐three (54%) were treated in the adjuvant setting. At the time of enrolment, 31 (51%) participants had active treatment for a previous irAE. Overall, 18/61 (30%) participants reported long‐term symptoms and trouble in physical and emotional functioning. Physical fatigue was common and interfered with daily activities ( n = 12, 20%). In the PRO‐CTCAE questionnaire, muscle ache ( n = 12, 20%) and joint ache ( n = 9, 15%) were commonly reported. Despite this, participants reported overall good health (6.00, range 2.00–7.00) and reasonable level of HRQL (6.00, range 3.00–7.00). Discussion Melanoma survivors experience long‐term symptoms in physical and psychosocial HRQL domains after ICI treatment. These results underline the importance to address existing gaps in survivorship care, implement these findings in clinical practice and increase awareness for long‐term symptoms in these patients.

Year:

2023

Collaborators (22)

caroline robert

- Directeur de l’équipe «Résistance thérapeutique» dans l’Unité INSERM U 981 : Biomarqueurs prédicteurs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse

Université de Paris Faculté de Santé

FRANCE
View details

Maximilian Julve

Clinical Assistant Professor

Stanford University

UNITED STATES
View details

Govind Warrier

Assistant Professor of Oncology

Johns Hopkins University

UNITED STATES
View details

Lauren Haydu

Assistant Professor of Biostatistics

Mayo Clinic

UNITED STATES
View details

Werner Stenzel

Head of Neuromuscular Diagnostic and Research unit/ Professor Dr. med

Charité - Universitätsmedizin Berlin

GERMANY
View details

Yves Allenbach

-

FRANCE
View details

Reinhard Dummer

University Hospital of Zurich

SWITZERLAND
View details

Alexander M. Menzies

University of Sydney

AUSTRALIA
View details

Roger Olofsson Bagge

Professor

University of Gothenburg

SWEDEN
View details

Luca Musella

Staff Scientist

University Hospital Erlangen

GERMANY
View details

Michael A. Postow

Weill Cornell Medical College

UNITED STATES
View details

Christoph Hoeller

Associate Professor, Head of Skin Cancer Center

Medical University of Vienna

AUSTRIA
View details

Alexander Salava

Dermatologist

University of Helsinki

FINLAND
View details

Eftychia (Efi) Chatziioannou

University of Tübingen

GERMANY
View details

Elisabeth Livingstone

University Hospital Essen

GERMANY
View details

Ryan Sullivan

Harvard University

UNITED STATES
View details

Dirk Schadendorf

University Hospital Essen

GERMANY
View details

Paolo Antonio Ascierto

Full Professor

Università degli Studi di Napoli Federico II

ITALY
View details

Phil Cheng

Bioinformatician

University Hospital of Geneva

SWITZERLAND
View details

Jolien Kessels

Vrije Universiteit Brussel

BELGIUM
View details

Bart Neyns

Diensthoofd

Vrije Universiteit Brussel

BELGIUM
View details

Ines Pires da Silva

Medical Oncologist

University of Sydney

AUSTRALIA
View details